The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial

BACKGROUND: The aim of this study was to examine whether EndoPredict (EP), a novel genomic expression test, is effective in predicting local recurrence (LR)-free survival (LRFS) following surgery for breast cancer in postmenopausal women. In addition, we examined whether EP may help tailor local the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Fitzal, F, Filipits, M, Rudas, M, Greil, R, Dietze, O, Samonigg, H, Lax, S, Herz, W, Dubsky, P, Bartsch, R, Kronenwett, R, Gnant, M
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2015
Assuntos:
Genetics and Genomics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4402462/
https://ncbi.nlm.nih.gov/pubmed/25867274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.98
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados